THERAPY DOSSIER · th-22a8c978d624

Bone marrow-derived mesenchymal stromal cell-conditioned media (seven clonal rat MSC lines, passages 6 to 12)

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Ischaemia-reperfusion
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 26896360 ↗2015Reported benefit

Pretreatment with bone marrow-derived mesenchymal stromal cell-conditioned media confers pulmonary ischemic tolerance.

RatIschaemia-reperfusionOther / unspecifiedLong-Evans (pathogen-free, Harlan Sprague-Dawley)Malen = n=10 per conditioned media clone group; n=15 media-only con…Intratracheal instillation200 microlitres of conditioned media per animal30 minutes before ischaemia (pretreatment)

Model: Left lung warm ischaemia-reperfusion: left hilar non-crushing clamp for 90 minutes followed by 4 hours of reventilation and reperfusion

Five of seven conditioned media clones reduced injury severity; clones O and H gave the largest reduction in lung permeability (median 0.086, p=0.0021 and p=0.028). Protective conditioned media significantly reduced BAL IL-1 beta and TNF alpha (both p<0.0001) and absolute neutrophil counts (p=0.000…

Extraction: extract · Supplied extraction confidence: 0.93. Machine-extracted fields require source verification.

Loading the evidence…